Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Halozyme Therapeutics, Inc.

Takeda vs. Halozyme: A Decade of Profit Growth

__timestampHalozyme Therapeutics, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014526020001256834000000
Thursday, January 1, 20151058120001271973000000
Friday, January 1, 20161134850001173296000000
Sunday, January 1, 20172854610001274610000000
Monday, January 1, 20181417260001437534000000
Tuesday, January 1, 20191504460002201424000000
Wednesday, January 1, 20202242270002203504000000
Friday, January 1, 20213618970002462160000000
Saturday, January 1, 20225208120002783406000000
Sunday, January 1, 20236368920002832257000000
Monday, January 1, 20248559070002832257000000
Loading chart...

Unlocking the unknown

Gross Profit Trends: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and Halozyme Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Takeda has consistently demonstrated robust growth, with its gross profit soaring by approximately 125% from 2014 to 2023. This Japanese giant's financial prowess is evident, with profits peaking at around 2.83 trillion yen in 2023.

Conversely, Halozyme, a smaller player in the industry, has shown remarkable growth, albeit on a different scale. From 2014 to 2023, Halozyme's gross profit surged by over 1,100%, reaching a peak of 637 million dollars. This impressive growth trajectory underscores the company's innovative approach and strategic partnerships.

While Takeda's dominance is clear, Halozyme's rapid ascent highlights the dynamic nature of the pharmaceutical sector, where innovation and agility can lead to significant financial gains.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025